J. Heymach

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.

S. Swisher, J. Heymach, D. Gibbons, 2021, Lung cancer.

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.

J. Heymach, T. Mitsudomi, D. Harpole, 2021, Clinical lung cancer.

Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.

J. Roth, S. Swisher, J. Heymach, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Boris Sepesi, Ignacio I. Wistuba, John V. Heymach, 2018, Journal of Immunotherapy for Cancer.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Edward S. Kim, Diane D. Liu, I. Wistuba, 2017, The Annals of thoracic surgery.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

I. Wistuba, S. Swisher, J. Heymach, 2019, Journal of Clinical Oncology.

P2.04-90 Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, M. Godoy, 2019, Journal of Thoracic Oncology.

Molecular and Cellular Pathobiology Tumor Endothelial Markers De fi ne Novel Subsets of Cancer-Speci fi c Circulating Endothelial Cells Associated with Antitumor Ef fi cacy

J. Heymach, R. Mehran, R. Schier, 2014 .

Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?

J. Heymach, T. Cascone, J. Heymach, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Michael Peyton, John D. Minna, Lixia Diao, 2013, Clinical Cancer Research.

Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors

J. Heymach, P. Zage, T. Cascone, 2010, Oncogene.

Emerging antiangiogenic agents in lung cancer.

J. Heymach, David J. Lee, J. Heymach, 2006, Clinical lung cancer.

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

John V Heymach, Thomas J Lynch, J. Meyerhardt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus

K. Coombes, J. Minna, M. You, 2012, PloS one.

Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.

G. Scagliotti, T. Nakano, J. Heymach, 2019, Seminars in oncology.

Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.

Joe Y. Chang, Xiaodong Zhang, Steven H. Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis

Suzie K. Hight, J. Minna, I. Wistuba, 2020, Neoplasia.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.

Joe Y. Chang, P. Thall, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions

A. El‐Naggar, J. Heymach, C. Caulin, 2017, Cancer Prevention Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%

S. Digumarthy, J. Roth, M. Mino‐Kenudson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.

S. Digumarthy, J. Heymach, M. Hellmann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long‐Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Joe Y. Chang, D. Gomez, P. Balter, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.

Xifeng Wu, J. Roth, Y. Ye, 2017, Lung cancer.

The histologic phenotype of lung cancers may be driven by transcriptomic features rather than genomic characteristics

P. A. Futreal, Xin Hu, I. Wistuba, 2021, bioRxiv.

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Susan M. Chang, M. Prados, M. Gilbert, 2013, Targeted Oncology.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Susan M. Chang, A. M. López, R. Schilsky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence

K. Coombes, G. Mills, Jing Wang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

P. A. Futreal, Xin Hu, I. Wistuba, 2020, Clinical Cancer Research.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

J. Weinstein, K. Coombes, G. Mills, 2012, Cancer discovery.

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition.

Abena B. Redwood, Jing Wang, T. Pandita, 2018, Cancer research.

Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Jing Wang, J. Heymach, L. Byers, 2017, Clinical Cancer Research.

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Jing Wang, I. Wistuba, J. Heymach, 2017, Oncotarget.

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer

Jing Wang, J. Heymach, L. Byers, 2017, Clinical Cancer Research.

Identi fi es a Novel AXL – PI 3 Kinase – PD-L 1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Jing Wang, Y. Liu, J. Heymach, 2017 .

An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2

G. Mills, Jing Wang, J. Minna, 2015, Clinical Cancer Research.

Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses

J. Heymach, C. Tacchetti, F. Bertolini, 2009, Clinical Cancer Research.

Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.

Jing Wang, J. Minna, I. Wistuba, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

J. Heymach, M. Hellmann, M. Nishino, 2020, Journal for ImmunoTherapy of Cancer.

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

J. Heymach, M. Hellmann, M. Nishino, 2020, Journal for ImmunoTherapy of Cancer.

Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.

P. Scheet, Jing Wang, I. Wistuba, 2019, American journal of respiratory and critical care medicine.

RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer

Jing Wang, I. Wistuba, Rui Ye, 2017, Clinical Cancer Research.

Control of HIF-1A Expression by eIF2A Phosphorylation-Mediated Translational Repression

J. Heymach, D. McConkey, M. Wilkinson, 2009 .

Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.

J. Heymach, D. McConkey, M. Wilkinson, 2009, Cancer research.

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

J. Heymach, F. Skoulidis, J. Heymach, 2019, Nature Reviews Cancer.

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

J. Heymach, P. Paik, A. Tsao, 2021, JCO Precision Oncology.

BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).

K. Coombes, J. Lee, W. Hong, 2013 .

Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain

M. King, J. Heymach, N. Muzyczka, 1999, Neuroscience.

Quantitative Evaluation of Drug-induced Microvascular Constriction in Mice Kidney Using a Novel Tool for 3D Geometrical Analysis of Ex vivo Organ Vasculature

J. Heymach, Y. Ramot, A. Nyska, 2014, Toxicologic pathology.

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

J. Minna, S. Lippman, I. Wistuba, 2012, Molecular Cancer Therapeutics.

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma

K. Ashizawa, Xin Hu, P. Scheet, 2019, Nature Communications.

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers

Jing Wang, K. Hunt, J. Heymach, 2016, Molecular Cancer Research.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

P. A. Futreal, Xin Hu, I. Wistuba, 2021, medRxiv.

Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer

J. Minna, Xian-Jin Xie, J. Heymach, 2014, Scientific Reports.

HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.

D. Hayes, Kwok-Kin Wong, W. Kaelin, 2009, The Journal of clinical investigation.

Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer

Joe Y. Chang, K. Ahrar, D. Gomez, 2018, JAMA network open.

Stereotactic Ablative Radiotherapy is a Highly Effective Treatment for Early Stage Non-Small Cell Lung Cancer in Elderly Patients

Joe Y. Chang, J. Welsh, J. Heymach, 2018 .

Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non–Small Cell Lung Cancer Using Conditional Survival Analysis

D. Gomez, R. Komaki, Z. Liao, 2015, American journal of clinical oncology.

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers

P. A. Futreal, I. Wistuba, S. Swisher, 2020, Journal of thoracic disease.

Genomic and TCR Repertoire Intratumor Heterogeneity of Small-cell Lung Cancer and its Impact on Survival

Xin Hu, Jing Wang, Roman K. Thomas, 2020, bioRxiv.

Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis

K. Coombes, Jing Wang, J. Minna, 2016, Cancer informatics.

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

R. Herbst, J. Heymach, A. Ryan, 2007, Expert opinion on investigational drugs.

ZD6474 – clinical experience to date

J. Heymach, J. Heymach, 2005, British Journal of Cancer.

Bevacizumab beyond disease progression for advanced non–small cell lung cancer: Does persistence have its rewards?

J. Heymach, E. Roarty, I. Guijarro-Muñoz, 2016, Cancer.

Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials.

J. Lee, D. Gomez, J. Welsh, 2017, International journal of radiation oncology, biology, physics.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2006, Clinical Cancer Research.

7‐year follow‐up after stereotactic ablative radiotherapy for patients with stage I non–small cell lung cancer: Results of a phase 2 clinical trial

Joe Y. Chang, J. Roth, D. Gomez, 2017, Cancer.

Simplified Molecular Classification of Lung Adenocarcinomas Based on EGFR, KRAS, and TP53 Mutations

M. Guo, J. Heymach, M. Routbort, 2019 .

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Mark M. Davis, P. A. Futreal, R. Emerson, 2020, Nature Communications.

Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.

J. Folkman, S. Soker, A. Atala, 2003, Cancer research.

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer

J. Heymach, Jianjun Zhang, E. Ostrin, 2022, JCI insight.

FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner

J. Heymach, C. Pickering, A. Osman, 2022, bioRxiv.

miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer1

J. Heymach, M. Story, L. Ding, 2019, Neoplasia.

Metabolic diversity in human non-small cell lung cancer

B. Faubert, R. Deberardinis, J. Minna, 2014, bioRxiv.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

R. Herbst, J. Heymach, F. D. De Braud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

J. Roth, J. Lee, S. Swisher, 2022, JAMA network open.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, J. Heymach, 2019, Cancer cell.

The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention

S. Lippman, J. Heymach, J. Heymach, 2007, Clinical Cancer Research.

Biology of Human Tumors VEGF / VEGFR-2 Upregulates EZH 2 Expression in Lung Adenocarcinoma Cells and EZH 2 Depletion Enhances the Response to Platinum-Based and VEGFR-2 – Targeted Therapy

K. Coombes, Jing Wang, J. Minna, 2014 .

VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy

K. Coombes, Jing Wang, J. Minna, 2014, Clinical Cancer Research.

Mesothelioma and small cell lung cancer.

J. Heymach, A. Tsao, J. Heymach, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

J. Heymach, G. Shapiro, H. Burris, 2010 .

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

J. Heymach, L. Tye, H. Lenz, 2015, British Journal of Cancer.

Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

W. Hong, I. Wistuba, J. Lee, 2014, Clinical lung cancer.

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

C. Ng, J. Heymach, A. Sood, 2011, The Lancet. Oncology.

In Response.

J. Heymach, X. Le, J. Heymach, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.

P. Brown, H. Parnes, S. Lippman, 2007, Cancer research.

Can the Lung Cancer Pie Be Divided into Angiogenic Slices?

J. Heymach, T. Cascone, J. Heymach, 2015, Clinical Cancer Research.

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

R. Herbst, J. Heymach, J. Hou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evolution of the DNA methylome from precancer to invasive lung adenocarcinoma

P. Scheet, I. Wistuba, N. McGranahan, 2020, medRxiv.

Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.

I. Wistuba, J. Heymach, R. Broaddus, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib.

Jing Wang, I. Wistuba, J. Heymach, 2017, JCO precision oncology.

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

R. Herbst, J. Heymach, A. Ryan, 2008 .

miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

Diane D. Liu, C. Creighton, J. Heymach, 2010, Molecular Cancer Research.

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

K. Hess, J. Heymach, F. Meric-Bernstam, 2020, ESMO Open.

Definitive Management of Presumed Synchronous Early-Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiotherapy.

Joe Y. Chang, J. Welsh, J. Heymach, 2020, International Journal of Radiation Oncology, Biology, Physics.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer

J. Minna, J. Roth, I. Wistuba, 2017, Clinical Cancer Research.

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

E. Jonasch, J. Heymach, H. Tran, 2009, Cancer.

Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer

K. Ang, S. Lippman, W. Hong, 2010, Molecular Cancer Therapeutics.

Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

J. Heymach, L. Byers, C. Pickering, 2014, Head & neck.

Blood-Based Biomarkers of SU 11248 Activity and Clinical Outcome in Patients withMetastatic Imatinib-Resistant Gastrointestinal

J. Heymach, D. Shalinsky, S. DePrimo, 2007 .

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

J. Manola, J. Desai, J. Folkman, 2007, Clinical Cancer Research.

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients withMetastatic Imatinib-Resistant Gastrointestinal StromalTumor

J. Heymach, D. Shalinsky, S. DePrimo, 2007 .

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Joe Y. Chang, K. Hess, J. Welsh, 2020, Journal for ImmunoTherapy of Cancer.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

John V Heymach, Kevin R Coombes, Lixia Diao, 2012, Journal of the National Cancer Institute.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

John V Heymach, Young-Ho Ahn, Roy S Herbst, 2013, Cancer research.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

Edward S. Kim, S. Lippman, W. Hong, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Profiles of brain metastases: Prioritization of therapeutic targets

R. Verhaak, P. Brastianos, N. Ibrahim, 2018, International journal of cancer.

Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept

M. Prados, M. Gilbert, M. Mehta, 2011, Clinical Cancer Research.

A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma

Jeffrey W. Clark, N. Holalkere, D. Sahani, 2005 .

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer

E. Dmitrovsky, J. Heymach, A. Vaporciyan, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

I. Wistuba, J. Lee, S. Swisher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity

P. A. Futreal, A. Lucas, Xin Hu, 2020, Genome Biology.

Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer.

Joe Y. Chang, D. Gomez, J. Welsh, 2019, Clinical lung cancer.

Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors

J. Heymach, A. Zurita, J. Mateo, 2012, Molecular Diagnosis & Therapy.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers

I. Wistuba, P. Sharma, J. Heymach, 2017 .

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

I. Wistuba, J. Lee, J. Heymach, 2021, Cancer Immunology, Immunotherapy.

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.

J. Roth, I. Wistuba, J. Lee, 2020, Clinical lung cancer.

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

M. Socinski, R. Govindan, Kwok-Kin Wong, 2007, Clinical Cancer Research.

OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues

R. Emerson, M. Vignali, I. Wistuba, 2017 .

Association of the T-cell receptor landscape with survival in non-small cell lung cancer.

Xifeng Wu, I. Wistuba, J. Lee, 2018 .

Abstract 2741: Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer

I. Wistuba, S. Swisher, G. Rao, 2019, Tumor Biology.

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.

I. Wistuba, J. Lee, R. Herbst, 2020, Clinical radiology.

The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.

Edward S. Kim, W. Hong, I. Wistuba, 2014 .

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

M. Socinski, J. Heymach, X. Le, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SABR vs surgery for NSCLC in the media.

S. Swisher, J. Heymach, A. Vaporciyan, 2015, The Lancet. Oncology.

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

J. Heymach, A. Tsao, L. Byers, 2022, Cancer cell.

Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.

Steven H. Lin, Z. Liao, J. Heymach, 2020, Clinical lung cancer.

Subcellular localization of epitope‐tagged neurotrophins in neuroendocrine cells

E. Shooter, J. Heymach, A. Krüttgen, 1998, Journal of neuroscience research.

Endothelial progenitor cell mobilization by preoperative exercise: a bone marrow response associated with postoperative outcome.

J. Heymach, R. Mehran, R. Schier, 2014, British journal of anaesthesia.

Molecular and Cellular Pathobiology The SUMOE 3-ligase PIAS 1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA

J. Teruya-Feldstein, L. Girard, J. Heymach, 2012 .

Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma

Jing Wang, M. McArthur, J. Heymach, 2020, Cancer Prevention Research.

Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248

J. Desai, G. Demetri, J. Heymach, 2005 .

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study.

R. Herbst, P. Fidias, J. Heymach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

R. Herbst, J. Heymach, D. Prager, 2005 .

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results.

R. Herbst, J. Heymach, D. Prager, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel therapeutic combination for neuroblastoma

J. Heymach, P. Zage, M. Nilsson, 2010, Cancer.

Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)

Edward S. Kim, J. Lee, J. Heymach, 2007 .

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

I. Wistuba, S. Swisher, R. Herbst, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)

Edward S. Kim, J. Weinstein, K. Coombes, 2011 .

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.

J. Heymach, J. D. de Groot, A. Zurita, 2012, Neuro-oncology.

Cediranib targeting of circulating VEGFR-1+ monocyte subpopulations

J. Heymach, J. Drevs, A. Zurita, 2008 .

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

Joe Y. Chang, K. Hess, D. Gomez, 2019, Cancer Immunology Research.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.

P. Scheet, I. Wistuba, S. Swisher, 2022, Lung cancer.

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

Joe Y. Chang, J. Welsh, Steven H. Lin, 2020, The Lancet. Respiratory medicine.

Metabolic diversity in human non-small cell lung cancer

B. Faubert, R. Deberardinis, J. Minna, 2014, bioRxiv.

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

J. Riess, J. Heymach, M. Hellmann, 2019, Journal of Clinical Oncology.

P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

S. Swisher, J. Heymach, A. Reuben, 2018, Journal of Thoracic Oncology.

Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis.

S. Lippman, I. Wistuba, J. Lee, 2017 .

Abstract 4686: T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma

P. Scheet, W. Hong, I. Wistuba, 2018, Immunology.

P2.02-013 Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing

J. Fujimoto, Xin Hu, W. Hong, 2017 .

P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

L. Trani, J. Taube, J. Heymach, 2019, Journal of Thoracic Oncology.

Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy.

J. Heymach, M. Godoy, W. William, 2017 .

Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome

M. Atkins, J. Heymach, A. Zurita, 2008 .

About CD45−/CD31+/CD105+ Circulating Cells in Patients with Gynecologic Malignancies—Letter

J. Heymach, F. Bertolini, P. Mancuso, 2014, Clinical Cancer Research.

Cytometry and Molecular and Ultrastructural Analyses Circulating Endothelial Cells and Progenitors : Flow Validation of a Standardized Method for Enumerating

J. Heymach, F. Bertolini, A. Zurita, 2008 .

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

J. Lee, J. Heymach, D. Gibbons, 2022, Cancers.

Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

Hu, Shuai, Alexa, 2020 .

Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.

Jing Wang, I. Wistuba, J. Heymach, 2022, JCO clinical cancer informatics.

Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.

J. Heymach, L. Tye, H. Lenz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endothelial progenitor cells contribute to accelerated liver regeneration.

J. Folkman, J. Heymach, T. Udagawa, 2007, Journal of pediatric surgery.

Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing.

Christopher S. Stevenson, L. Tran, P. Scheet, 2021, Cancer discovery.

Abstract 4421: Onco Vasculomics(tm): A 3-d tumor vasculature assessment methodology for quantifying mechanism and efficacy of discovery-stage anti-cancer compounds.

G. Naumov, J. Heymach, Yanchun Wu, 2013 .

O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial

R. Herbst, P. Fidias, J. Heymach, 2005 .

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

C. Rudin, J. Minna, Roman K. Thomas, 2019, Nature Reviews Cancer.

Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse

I. Wistuba, Yamei Chen, J. Heymach, 2018, Tumor Biology.

Abstract 5648: Combined immune checkpoint targeting with anti-PD-1 plus anti-CD40 antibodies as the most effective approach to eradicate head and neck squamous cell carcinomas (HNSCCs) in mouse models

J. Heymach, P. Hwu, W. William, 2017 .

Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06

Jie Yang, N. Reinmuth, E. Smit, 2018, The New England journal of medicine.

Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474

P. Jänne, J. Engelman, J. Folkman, 2005 .

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

A. D. Van den Abbeele, J. Manola, J. Desai, 2004, Clinical Cancer Research.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

I. Wistuba, J. Heymach, K. Kelly, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis

E. Jonasch, J. Heymach, P. Corn, 2008 .

The KRAS-variant and treatment response in BATTLE-1.

Edward S. Kim, F. Slack, Jun Yu, 2014 .

Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.

Hau D. Le, J. Heymach, Sendia Kim, 2008, The Journal of surgical research.

Inhibitio no fIntra-Abdomina lAdhesio nFormatio nWit hth eAngiogenesis Inhibito rSunitinib

Hau D. Le, J. Heymach, Sendia Kim, 2008 .

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

R. Schilsky, J. Heymach, J. D. de Groot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.

J. Heymach, X. Le, M. Nilsson, 2021, Cancer cell.

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

J. Heymach, Y. Xi, Q. Wang, 2020, Annals of Oncology.

Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer.

Joe Y. Chang, Steven H. Lin, X. Zhu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA08.01 Analysis of PD-L1 Expression on Circulating Stromal and Tumor Cells in Lung Cancer Patients Treated with Chemoradiation Therapy and Atezolizumab

Z. Liao, J. Heymach, A. Tsao, 2019, Journal of Thoracic Oncology.

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model

Joe Y. Chang, D. Gomez, J. Welsh, 2018, Clinical Cancer Research.

KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Jeffrey S. Morris, Jing Wang, J. Minna, 2020, American journal of cancer research.

Netie: inferring the evolution of neoantigen–T cell interactions in tumors

I. Wistuba, J. Heymach, A. Reuben, 2022, Nature Methods.

An IRAK1-PIN1 Signalling Axis Drives Intrinsic Tumour Resistance to Radiation Therapy

R. White, A. Schlessinger, J. Heymach, 2018, Nature Cell Biology.

Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study

E. Diamandis, J. Heymach, D. Gerber, 2022, Clinical chemistry and laboratory medicine.

Investigation of PARP1 as a therapeutic target in small cell lung cancer.

J. Weinstein, K. Coombes, Jing Wang, 2012 .

Development and validation of an ultra-deep next-generation sequencing assay for 1 testing of plasma cell-free DNA from patients with advanced cancer 2

G. Mills, S. Gnerre, Richard Shen, 2017 .

Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC).

J. Heymach, C. Sternberg, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

E. Smit, J. Heymach, Keunchil Park, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy

S. Swisher, J. Heymach, A. Vaporciyan, 2022, JTO clinical and research reports.

Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF.

E. Shooter, J. Heymach, U. Suter, 1991, The EMBO journal.

The mutually regulatory loop of epithelial–mesenchymal transition and immunosuppression in cancer progression

J. Heymach, D. Gibbons, F. X. Qin, 2015, Oncoimmunology.

Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.

D. Gomez, S. Swisher, G. Rao, 2014, International journal of radiation oncology, biology, physics.

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With PD-1/PD-L1 Blockade−Resistant Advanced Non−Small Cell Lung Cancer

J. Heymach, A. Tsao, V. Papadimitrakopoulou, 2022, JTO Clinical and Research Reports.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Bene ﬁ t from Immune Checkpoint Blockade than HLA Class I Genotype in Non – Small Cell Lung Cancer

J. Roth, I. Wistuba, J. Lee, 2022 .

roid Receptor Coactivator-3 Expression in Lung cer and Its Role in the Regulation of Cancer Cell

J. Pollack, J. Minna, I. Wistuba, 2010 .

Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma.

P. Jänne, E. V. Van Allen, J. Heymach, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.

D. Gomez, S. Swisher, Steven H. Lin, 2012, International journal of radiation oncology, biology, physics.